Intelligent Bio Solutions, Inc. operates as a biosensor diagnostic technology company. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

The full company name is Gui Bin She International Holding Group.

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study.

GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study

GBS Inc. (GBS) CEO Steven Boyages on Q1 2022 Results - Earnings Call Transcript

– Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test –

GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced changes to its executive leadership team as the Company advances into a new phase focused on product development and planned manufacturing.

GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensees, GBS Inc (Nasdaq: GBS); a life sciences company operating in the Asia Pacific region, under license from LSBD, to commercialize its non-invasive, real-time Glucose Salivary test; has filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA). The purpose of this Pre-Submission is to confirm with the FDA the clinical trial design, including trial objectives.

FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA). The purpose of this pre-submission is to confirm with the FDA that GBS is following the proper steps to conduct the clinical studies enabling it to develop the glucose biosensor according to the FDA regulatory standards.

GBS Inc. Announces its Pre-Submission package is with the FDA

H.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th

GBS Inc. to Present at Upcoming September Virtual Investor Conferences

The stock price of GBS Inc (NASDAQ: GBS) increased by over 40% pre-market. These are some details you should know.

GBS Stock: Over 40% Increase Pre-Market Explanation

GBS is a biotechnology company aiming to utilize saliva as a medium for developing non-invasive diagnostic tests. The companies pipeline products are targeting both the COVID-19 and Diabetes markets.

GBS Inc.: Can Its Technology Come Through?

GBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021. For some people with diabetes, testing with a pinprick is no more than a minor inconvenience.

Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing

GBS Inc. (GBS) CEO Harry Simeonidis on Q4 2021 Results - Earnings Call Transcript

GBS Inc. is a developer of pioneering diagnostic platform adaptable to large unmet markets with multiple applications and indications.

GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has been awarded a USD $4.7 million, Australian Federal Government scientific grant to fund the build out of a Biosensor manufacturing facility. This project has been identified as one of six National Manufacturing Priorities identified by the Government under Modern Manufacturing Strategy (MMS).

GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology

Progenity

Transocean

Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?

Hot Penny Stocks to Buy Under $5? 3 You Might Not Have Heard Of

The stock price of GBS Inc (NASDAQ: GBS) increased by over 45% pre-market. These are the details.

GBS Stock Price: Over 45% Increase Pre-Market Explanation

Global results show 90% of patients are in favor of a saliva-based glucose test Global results show 90% of patients are in favor of a saliva-based glucose test

Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick' Alternative in Global Glucose Monitoring Survey

- Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021-

GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute) have received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a validation study to test clinical samples from a COVID-19 repository.

GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of next-generation saliva-based diagnostic tests.

GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care, today announced the closing of its previously announced initial public offering of 1,270,589 units of its securities, which amount reflected the 20% upsizing of the offering that was implemented at the time of pricing. Each unit was sold at the price of $17.00 and immediately separated into (a) one share of the Company's common stock, (b) one Series A Warrant to purchase one share of the Company's common stock at an exercise price equal to $8.50 per share exercisable until the 5th anniversary of the issuance date, and (c) one Series B Warrant to purchase one share of the Company's common stock at an exercise price equal to $17.00 per share exercisable until the 5th anniversary of the issuance date and subject to certain adjustment and cashless exercise provisions as described herein. The Series B Warrants contain an exchange feature that permit the holder to exchange the warrant into shares of common stock on a one-for-one basis any time commencing the earlier of 10 days from the IPO or the time when $10 million of volume is traded in the common stock (which has already occurred) if the closing stock price of the common stock on the date of exercise is below the exercise price of the Series B Warrant. The Company intends to use the net proceeds from this offering for obtaining regulatory approvals, marketing and establishing a distribution network, in addition to working capital. The gross proceeds from the offering were approximately $21.6 million before deducting underwriting discounts, commissions and offering expenses.

GBS, Inc. Announces Closing of Upsized $21.6 Million Initial Public Offering

Inhibikase Therapeutics

GBS and Inhibikase Therapeutics priced late Tuesday.

2 More IPOs Make Their Trading Debuts Today

Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”

UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care, today announced the pricing of its initial public offering of 1,270,589 units at a public offering price of $17.00 per unit. Each unit will immediately separate into (a) one share of the Company's common stock (or, at the purchaser's election, one share of Series B Convertible Preferred Stock), (b) one Series A warrant (the “Series A Warrants”) to purchase one share of the Company's common stock at an exercise price equal to $8.50 per share exercisable until the 5th anniversary of the issuance date, and (c) one Series B warrant to purchase one share of the Company's common stock at an exercise price equal to $17.00 per share exercisable until the 5th anniversary of the issuance date and subject to certain adjustment and cashless exercise provisions as described herein.

News for GBS Stock (GBS)